Rosiglitazone/glimepiride

Drug Profile

Rosiglitazone/glimepiride

Alternative Names: Avaglim; Avandaryl

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Insulin sensitisers; Sulfonylureas; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 23 May 2011 The US FDA places further restrictions on rosiglitazone-containing drugs
  • 08 Feb 2011 GlaxoSmithKline revises US prescription information for rosiglitazone-containing medicines
  • 24 Sep 2010 The EMA suspends the marketing authorisation for all rosiglitazone-containing medicines in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top